Close Menu

Vela Diagnostics

The company said that it has achieved encouraging results in a preclinical study of the assay, and that if clinical trial results are equally positive it will submit the test for US Food and Drug Administration approval by the end of the summer.

The company has developed a cartridge-based, multiplex, sample-to-answer molecular testing platform in the same vein as Cepheid, and hopes to begin clinical trials for its first two tests for detecting Staphylococcus aureus in blood culture and Clostridium difficile in stool by early summer.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.